Ken Griffin Crispr Therapeutics Ag Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Citadel Advisors LLC holds 425,500 shares of CRSP stock, worth $15.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

425,500

Previous 292,300 45.57%

Holding current value

$15.8 Million

Previous $11.5 Million 25.86%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$34.03 - $53.02 $21.1 Million - $32.9 Million	-621,349 Reduced 70.7%	257,547 $8.76 Million
Q4 2024 Feb 14, 2025	BUY	$38.65 - $55.15 $13.9 Million - $19.9 Million	360,349 Added 69.49%	878,896 $34.6 Million
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $16.8 Million - $23.6 Million	375,985 Added 263.73%	518,547 $24.4 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $4.84 Million - $6.45 Million	-94,538 Reduced 39.87%	142,562 $7.7 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $2.2 Million - $3.23 Million	-36,259 Reduced 13.26%	237,100 $16.2 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $9.72 Million - $18.2 Million	251,804 Added 1168.19%	273,359 $17.1 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $3.01 Million - $3.92 Million	-66,410 Reduced 75.5%	21,555 $978,000
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $3.75 Million - $5.85 Million	-86,374 Reduced 49.54%	87,965 $4.94 Million
Q1 2023 May 15, 2023	BUY	$41.0 - $56.12 $181,425 - $248,331	4,425 Added 2.6%	174,339 $7.89 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $6.44 Million - $10.8 Million	164,324 Added 2939.61%	169,914 $6.91 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $159,959 - $219,336	-2,618 Reduced 31.9%	5,590 $365,000
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $8.78 Million - $15 Million	-203,205 Reduced 96.12%	8,208 $499,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $4.1 Million - $6.11 Million	77,094 Added 57.4%	211,413 $13.3 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $5.87 Million - $9.32 Million	-83,702 Reduced 38.39%	134,319 $10.2 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $19.3 Million - $27.4 Million	174,687 Added 403.12%	218,021 $24.4 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $23.4 Million - $37.6 Million	-232,439 Reduced 84.29%	43,334 $7.02 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $23.2 Million - $43.9 Million	209,209 Added 314.3%	275,773 $33.6 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $2.57 Million - $5.59 Million	32,291 Added 94.22%	66,564 $10.2 Million
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $1.65 Million - $2.11 Million	20,968 Added 157.59%	34,273 $2.87 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $744,744 - $1.47 Million	-19,344 Reduced 59.25%	13,305 $978,000
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $5.88 Million - $10.9 Million	-174,609 Reduced 84.25%	32,649 $1.39 Million
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $5.35 Million - $10.7 Million	145,750 Added 236.96%	207,258 $12.6 Million
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $755,386 - $1.41 Million	33,233 Added 117.53%	61,508 $1.76 Million
Q3 2018 Nov 13, 2018	SELL	$44.35 - $65.71 $2.98 Million - $4.42 Million	-67,206 Reduced 70.39%	28,275 $0
Q2 2018 Aug 10, 2018	BUY	$42.62 - $73.59 $1.78 Million - $3.07 Million	41,785 Added 77.82%	95,481 $0
Q1 2018 May 11, 2018	BUY	$23.52 - $58.17 $326,575 - $807,690	13,885 Added 34.88%	53,696 $2.45 Million
Q4 2017 Feb 09, 2018	BUY	$16.95 - $23.48 $674,796 - $934,762	39,811	39,811 $935,000

Others Institutions Holding CRSP

# of Institutions

479

Shares Held

64.2M

Call Options Held

2.15M

Put Options Held

1.92M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $2.9B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account